|Bid||133.02 x 100|
|Ask||133.04 x 200|
|Day's Range||132.57 - 133.82|
|52 Week Range||109.32 - 137.08|
|PE Ratio (TTM)||22.43|
|Dividend & Yield||3.36 (2.48%)|
|1y Target Est||N/A|
Pfizer Inc. sued Johnson & Johnson Wednesday in the latest twist to the heated and protracted battle over biosimilar competition for a multibillion-dollar blockbuster medicine originally developed by Centocor. The lawsuit further alleges that Johnson & Johnson’s systematic efforts to maintain its monopoly in connection with Remicade — a product it acquired when it bought Malvern-based Centocor for $4.9 billion in 1999 — violate federal antitrust laws and undermines the principal goals of the U.S. Biologics Price Competition and Innovation Act, which became law 2010.
If you want your portfolio to last throughout your retirement, you need to invest in a way to protect your long-term purchasing power as well as your current costs of living. These three companies could very well play a solid role in that part of your portfolio.
Pfizer is suing Johnson & Johnson, alleging that it set up contracts to leave Pfizer’s Inflectra out in the cold.